07.19.09
#14 Takeda
1-1, Doshomachi 4-chome Chuo-ku, Osaka 540-8645, Japan
Tel: (81) 66 204 2111
Fax: (81) 66 204 2880
www.takeda.com
Headcount | 19,362 | |
Year Established | 1781 | |
Pharma Revenues | $13,841 | +30%/+14%* |
Total Revenues | $15,383 | +27%/+12%* |
Net Income | $2,344 | -25%/-34%* |
R&D Budget | $4,530 | +87%/+64%* |
* converted at avg. exch. rate / based on local currency (JPY)
2008 Top Selling Drugs | |||
Drug | Indication | Sales | (+/-%) |
Actos | diabetes | $3,870 | +11% |
Prevacid | GERD | $2,714 | +108% |
Blopress | hypertension | $2,303 | +18% |
Lupron | prostate cancer | $1,261 | +16% |
Account for 73% of total pharma sales, down from 74% in 2007.
PROFILE
Takeda took a jump up our charts this year, as it incorporated some revenues from TAP (and Millennium, to a lesser extent), its former joint venture with Abbott, which was dissolved last year after a 30-year run. The big boost came with Prevacid revenues, which now go directly to Takeda, more than doubling the company’s take from the previous year. Prevacid’s patent expires in the U.S. late in 2011, while the basic version of its top seller, diabetes drug Actos, expires earlier that year. In constant currency, Actos’ sales slipped slightly in 2008, but U.S. revenues from all Actos products were up nearly 8% to $3.0 billion.
Acquisition News
Target: IDM Pharma Price: $67 million Announced: May 2009 What they said: “We envisage that [MEPACT, IDM’s osteosarcoma drug] will become a key driver in enhancing our European oncology franchise.”—company statement |
Takeda was hoping to smooth out the valley of Actos’ expiration by marketing a combo of Actos and the company’s DPP-IV inhibitor, alogliptin. At the very least, it was hoping to get alogliptin on the market by itself, in order to make some headway into the Type 2 diabetes market, but the company received not-so-good news from U.S. and EU regulators on the project. In March 2009, the FDA informed Takeda that, despite submitting alogliptin’s NDA in December 2007, it would still be subject to a new guidance of CV risk for Type 2 diabetes treatments that was issued one year later. That led the FDA to request an additional Phase III trial of alogliptin.
The company will also conduct a long-term Phase III trial of alogliptin in Europe, pitting it against glipzide (Glucotrol), pushing the expected submission of the MAAs of the DPP-IV inhibitor and the Actos-combo from mid-2009 to sometime in 2012. The FDA decision likely won’t come till 2013. So that’s not good.
Still, the company did get FDA approval of an Actos/metformin XR combo in May 2009, so it will be able to expand its Actoplus Met franchise in that field while negotiating alogliptin’s submissions. In addition, two of the drugs from the TAP pipeline, Kapidex (GERD) and Uloric (hyperuricemia in gout) received FDA approval in 2009.
The integration of TAP has given Takeda has a ready-built U.S. infrastructure, and the company has continued its expansion efforts last year by establishing operations in Canada and boosting sales and marketing forces in several European markets. But with all of its new branches, the company has had to reorganize its executive structure, creating new roles of chief scientific officer, chief administration officer, and executive vice president of international operations. We’ll see if it helps Takeda achieve its goal of becoming a global pharmaceutical company.